Kshipra Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 03-01-2025
- Paid Up Capital ₹ 9.20 M
as on 03-01-2025
- Company Age 27 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 Cr
as on 03-01-2025
- Revenue 61.42%
(FY 2022)
- Profit 31.55%
(FY 2022)
- Ebitda -6.91%
(FY 2022)
- Net Worth 3.07%
(FY 2022)
- Total Assets -4.68%
(FY 2022)
About Kshipra Drugs
The Corporate was formerly known as Kshipra Metals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.20 M.
The company currently has active open charges totaling ₹1.00 Cr.
Joginder Pandit and Jitendra Prasad serve as directors at the Company.
- CIN/LLPIN
U27105MP1997PTC011846
- Company No.
011846
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Apr 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- LocationDewas, Madhya Pradesh
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Kshipra Drugs Private Limited offer?
Kshipra Drugs Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Pain Relief Drugs & Pharmaceuticals, Muscle Relaxant, Multivitamin Tablets & Capsules, Mineral Supplement, Common Disease Medicines, Antihistamines, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup.
Who are the key members and board of directors at Kshipra Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Joginder Pandit  | Director | 21-Apr-1997 | Current |
| Jitendra Prasad | Director | 09-Feb-2019 | Current |
Financial Performance of Kshipra Drugs.
Kshipra Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 61.42% increase. The company also saw a substantial improvement in profitability, with a 31.55% increase in profit. The company's net worth moved up by a moderate rise of 3.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kshipra Drugs?
In 2021, Kshipra Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 24 Nov 2003 | ₹1.00 M | Open |
Bank Of India Creation Date: 10 Feb 2003 | ₹9.00 M | Open |
How Many Employees Work at Kshipra Drugs?
Unlock and access historical data on people associated with Kshipra Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kshipra Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kshipra Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
